هذا نص آخر أعلان أرباح ...
تأملوا نسبة الزيادة في الأرباح والمبيعات وصافي هامش الربح ...
AngioDynamics Fiscal Third Quarter Operating Profit Nearly Doubles on Net Sales Growth of 24%
Tuesday March 29, 4:02 pm ET
Conference Call to Begin Today at 4:30 p.m. ET
QUEENSBURY, N.Y.--(BUSINESS WIRE)--March 29, 2005--AngioDynamics, Inc. (Nasdaq:ANGO - News) today announced financial results for the 13 and 39 weeks ended February 26, 2005.
ADVERTISEMENT
Net sales for the third quarter of fiscal 2005 were $15.5 million, an increase of 24% over net sales of $12.5 million for the third quarter of fiscal 2004. This increase was primarily due to strong unit growth including the Company's newest products, along with continued gains across its entire diversified product portfolio. The faster-growing products included those in the Company's vascular access line, in particular its new Morpheus(TM) CT PICC (peripherally inserted central catheter) product.
Gross profit increased 29% to $8.6 million for the fiscal 2005 third quarter, from $6.7 million for the prior-year third quarter, and gross margin rose to 55.4% from 53.4%. The increase in gross margin reflects a product mix favoring sales of higher-margin products, lower materials costs resulting from purchase volume discounts with a major supplier and modest price increases implemented earlier this year. Operating profit for the quarter nearly doubled to $2.1 million, compared with $1.1 million in the prior-year third quarter.
Net earnings for the third quarter of fiscal 2005 rose 59% to $1.1 million, or $0.09 per diluted share, from $0.7 million, or $0.07 per diluted share, for the fiscal 2004 third quarter. Fiscal 2005 third quarter net earnings include a one-time impairment charge for the Company's entire investment in Surgica Corporation, a developer of embolic agents, of $300,000, or $0.02 per diluted share. The Company's effective income tax rate for the quarter was 43%, largely due to the investment impairment, for which no immediate tax benefit can be recognized. Without the impairment, the income tax rate for the quarter would have been approximately 37%.
"We are delighted to have handily exceeded our overall goal of 20% growth in net sales and, in spite of the one-time impairment charge, we also sharply exceeded our net profit goal of 35% growth, with strong contribution from our higher-margin products. Unit growth was excellent across our entire product line, and the uptake for our Morpheus CT PICC has been especially gratifying, with sales reaching $1.0 million in the quarter. The Morpheus CT PICC performance helped drive a sales increase in our image guided vascular access product segment of nearly 150% from the third quarter of last year," said Eamonn P. Hobbs, president and CEO of AngioDynamics.
"The Morpheus CT PICC product is being well received by the interventional radiology community due to its ability to be used for both contrast delivery during contrast-enhanced CT studies, as well as being an outstanding performer in the standard PICC line uses," he added. "Sales growth of this product is testament to its innovation, especially given that the product was launched only recently, in September 2004. Because the Morpheus CT PICC eliminates the need for a second access site, patient comfort is increased, while time is saved and costs are reduced."
Mr. Hobbs added, "While we continue to evaluate new product opportunities on a regular basis, a portion of our R&D budget has been allocated to create innovative, value-added opportunities for our existing product offering. Our strategy is to offer premium proprietary products. In addition to Morpheus, we are looking forward to highlighting some of these products -- such as Total Abscession(TM), a new drainage catheter and Tre Sheath(TM), a new hydrophilic coated, ultrasonically and fluoroscopically visible sheath for our VenaCure(TM) laser treatment for severe varicose veins -- at this week's Society for Interventional Radiology annual meeting in New Orleans."
AngioDynamics had cash and cash equivalents of $15.4 million and marketable securities of $9.6 million as of February 26, 2005, compared with $1.7 million and $0.7 million, respectively, as of May 29, 2004. The increases are due primarily to the receipt in June 2004 of the proceeds from the Company's initial public offering, in addition to the Company's positive operating cash flows.
For the 39 weeks ended February 26, 2005, net sales were $43.0 million, up 23% from net sales of $34.9 million for the comparable 2004 period, reflecting growth from newer products as well as continued gains in sales of existing product lines.
Net earnings for the first nine months of fiscal 2005 increased 81% to $2.9 million, or $0.24 per diluted share, from $1.6 million, or $0.16 per diluted share, for the first nine months of fiscal 2004. The increase was attributable primarily to increased sales, higher gross margins and reduced interest expense.
Commenting on financial guidance for the remainder of fiscal 2005, Mr. Hobbs said, "We expect net sales growth to be approximately 22%, while we expect net earnings to approach $4.2 million for the year. We affirm our expectation that R&D expenditures will be approximately 8% of net sales, and that SG&A expenses will be approximately 35% of net sales. We plan to add five members to our sales staff during the fourth quarter, bringing the total to 44 by the end of the current fiscal year."
Conference Call
AngioDynamics management will host a conference call to discuss this announcement today beginning at 4:30 p.m. Eastern Time. To participate in the call, please dial 877-815-7177 from the U.S., or 706-634-1250 from outside the U.S.
A telephone replay of the call will be available for 48 hours following completion of the call by dialing 888-642-1687 from the U.S., or 706-645-9291 from outside the U.S., and entering reservation number 4979020.
In addition, individuals may listen to the call on the Internet by visiting the investor relations portion of the Company's Web site at
www.angiodynamics.com. A recording of the conference call will be archived there for 12 months.
